atrasentan hydrochloride Report issue

Small molecule Experimental
AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1
  • InChIKey: MOTJMGVDPWRKOC-QPVYNBJUSA-N
  • Mol. Mass: 510.63
  • ALogP: 4.69
  • ChEMBL Molecules:
    atrasentan  
    atrasentan hydrochloride  
More Chemistry

Pharmacology

Alternative names

(11c)abt-627 | 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid | a 127722 | a-127722 | a-127722.5 | a 147627 | a-147627 | a-147627.1 | abbot-147627 | abt 627 | abt-627 | atrasentan | atrasentan hcl | atrasentan hydrochloride | xinlay

Organizations (17)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Adenocarcinoma (Phase 2/Phase 3)

Brain Neoplasms (Phase 1)

Diabetes Mellitus (Phase 2)

Diabetic Nephropathies (Phase 3)

Endothelial Cells (Phase 3)

Fallopian Tube Neoplasms (Phase 2)

Glomerulonephritis, IGA (Phase 3)

Glomerulosclerosis, Focal Segmental (Phase 2)

Hamartoma (Phase 2)

Kidney Diseases (Phase 2)

Kidney Neoplasms (Phase 2)

Neoplasms (Phase 3)

Nephritis, Hereditary (Phase 2)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 3)

Renal Insufficiency, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue